Contineum Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2023 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Contineum Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2023 to Q4 2024.
  • Contineum Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$14.6M, a 87.5% decline year-over-year.
  • Contineum Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$42.3M, a 286% decline year-over-year.
  • Contineum Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$42.3M, a 286% decline from 2023.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$42.3M -$14.6M -$6.8M -87.5% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-06
Q3 2024 -$35.5M -$10.3M -$4.02M -64.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$31.4M -$9.01M -$50.6M -122% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-06
Q1 2024 $19.1M -$8.42M -$3.59M -74.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-06
Q4 2023 $22.7M -$7.77M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-06
Q3 2023 -$6.25M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $41.6M Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-06
Q1 2023 -$4.82M Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.